In this episode of the JGO Podcast, we explore two Editor's Choice studies focused on ovarian cancer. First, we delve into the work of Nozaki and colleagues, who investigate the role of specific biomarkers in predicting patient responses to PARP inhibitors. Their findings challenge the conventional reliance on genomic instability scores alone and offer new insights into personalized treatment strategies. Next, we discuss the study by Yuan and colleagues, which examines how a history of breast cancer affects the response to PARP inhibitors in ovarian cancer patients with BRCA1/2 mutations. Tune in to discover how these groundbreaking studies could shape the future of ovarian cancer treatment.

Article #1: Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer (https://doi.org/10.3802/jgo.2024.35.e55)

Article #2: PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer (https://doi.org/10.3802/jgo.2024.35.e51)